Does CBN actually help you sleep?
Not on the evidence so far. CBN has been tested for sleep in people, and the trials missed the endpoints they set in advance. grade: Not supported
Leave cannabis in a jar long enough, in air and light, and some of its Δ9-THC turns into CBN as it ages. That by-product now sells in volume as the sleep cannabinoid. Three trials have tested that claim in people, and the scorecard is short. The two that named a primary endpoint in advance both missed it. The largest study in the literature found that adding CBN to a sleep formula changed nothing. And every dose that moved anything at all was 4–60× what a retail capsule contains, which leaves the product on the shelf selling a dose below anything the trials used.
Start with where CBN comes from, because the sleep story starts there too. The major cannabinoids grow on the enzymatic tree that starts at CBGA, the mother acid (the varins on a parallel tree from CBGVA), where a dedicated synthase commits substrate to each branch. CBN has no branch. It forms after the fact, as the tree's products Δ9-THC and THCA oxidise in oxygen, light and time. It gets there by two routes, and both run on ordinary chemistry rather than an enzyme built for the job.
THCA synthase, CBDA synthase and CBCA synthase each take the mother acid CBGA and turn it into a branch acid. CBN has no such enzyme, which sets it apart from every cannabinoid the plant builds on purpose; among the compounds we cover, only CBL, which light slowly makes from CBC, shares that kind of after-the-fact origin. It forms as Δ9-THC and THCA oxidise with exposure to air, light and time, which is why fresh plants carry mere traces while aged, oxidised or poorly stored material builds up more. The sleep supplement on the shelf is built on a degradation product.
Our registry holds no graded CBN record, and its biosynthesis records stop short of any oxidation pathway. Where /cbdv and /cbga each lean on a registry-graded study, CBN has no registry-graded citation at all. The papers that carry its story are published and checkable, and they stand on their own. Borrowing a loosely related record as an anchor would lend CBN a standing its own sources do not give it.
Six questions to put to a supplier, each followed by the position the registry or this compound's page already holds, in its own words. The questions ask what the supplier states; none asks what anyone should take. Informational only, not medical or legal advice.
Take the answers to the paperwork: Read a COA, then test the label wording. How the site grades what it holds is on How we grade.
Most minor cannabinoids run out of evidence because nobody has looked. CBN ran out because researchers did look. They ran trials built to answer the sleep question, and the endpoints those trials chose in advance came back null.
The right-hand column holds two kinds of gap. The sleep-efficacy rows were tested, and their pre-specified endpoints came back null, which makes them results. The ≤5 mg retail dose (Corroon 2021) and long-term safety are absences, because nobody has run those studies. A negative result and an absence of evidence are different things, and anyone writing a label needs to know which one they are standing on. A missed endpoint means the trial went looking for the effect it was built to detect and came back empty-handed. Calling that “mixed”, “promising” or “trending toward significance” misdescribes it, and so does filing it under “more research needed”. Our evidence ladder reserves Not-supported for evidence that weighs against a claim, and only our evidence registry assigns it.
Catalogue in progress: every CBN study cited on this page sits outside the registry and is marked so where it appears. When one is ingested through the gated pipeline, it lands here. Open the library →
Study design, not evidence grade. The rows say how a study was run; they say nothing about the standing of any claim. A tier describes a study; a grade describes a claim.
Three published trials have given people CBN specifically to test it for sleep. Rank them by strength of design and the largest, most positive one comes last: on every measure that decides whether a result can be trusted, it trails the other two. Before quoting any of them, check what was actually tested, and read the shows / does not show lines as a pair, since the headline tends to sit in one and the catch in the other.
The badge on each paper names its study design, and design is all it names. These papers are still outside the graded CBG Atlas registry, so they hold no rung on our evidence ladder yet, and none is used here as an authority. When one enters the registry, it arrives with its grade, like every other record.
What was actually tested: Run remotely from May to November 2022 and registered as NCT05839964, this double-blind, randomised, placebo-controlled trial gave each participant one of five treatments for seven consecutive nights: placebo, 20 mg CBN, or 20 mg CBN plus 10, 20 or 100 mg CBD. They were 18–55 years old and rated their own past-week sleep quality as “poor” or “very poor”, which made them people who judged their own sleep poor rather than patients with diagnosed insomnia. The registration lists the condition as “healthy adults” and records healthy volunteers. The modified intent-to-treat analysis covered n = 293.
The trial missed its primary endpoint. On sleep quality, 20 mg CBN against placebo gave an odds ratio of 2.26 (95% CI [0.93, 5.52], p = .082), an interval that crosses 1. Further down the hierarchy, two secondary endpoints reached significance: number of awakenings (p = .025) and overall sleep disturbance (p = .023). Three others came back null, as sleep-onset latency, wake after sleep onset and daytime fatigue all failed to separate from placebo (all p > .05). Adding CBD, at any of the three doses, failed to improve on CBN alone.
What it shows: That in adults who rate their own sleep as poor, 20 mg of CBN taken nightly for a week reduced self-reported night-time awakenings and overall sleep disturbance compared with placebo, both of them secondary measures. Daytime fatigue stayed where it was.
What it does NOT show: That CBN improved sleep quality, the very question the trial pre-specified and then missed. How long people took to fall asleep and how long they lay awake in the night were both measured, and both were null. And at 20 mg, the trial tells a buyer nothing about the ≤5 mg found in retail products.
Caveat: Industry wrote this one from end to end. Every listed author is affiliated with Canopy Growth Corporation except one, who is at Wana Brands, a cannabis-products company. With no results posted to the trial registration, the published paper is the entire public record, and any summary of the trial met elsewhere is worth checking against its registered endpoints.
What was actually tested: Here the patients were diagnosed. At the Woolcock Institute of Medical Research in Sydney, a randomised, double-blind, placebo-controlled, three-arm, single-night crossover enrolled 20 adults aged 25–65 with physician-diagnosed insomnia disorder (DSM-5 and ICSD-3 criteria, Insomnia Severity Index ≥ 15). On separate nights, in random order and with a two-week washout between them, each took a single oral dose of 30 mg CBN, 300 mg CBN and matched placebo while overnight in-laboratory polysomnography recorded their sleep. The trial is registered as NCT05344170 under the acronym CUPID, the trial's name rather than the paper's title. Twenty participants and one night per arm make it a proof-of-concept study, and the registration calls it one.
The primary endpoint missed at both doses. Wake after sleep onset moved by −6.3 minutes at 300 mg (95% CI [−18.2, +5.5], p = 0.29) and −4.0 minutes at 30 mg (95% CI [−15.9, +7.9], p = 0.50), neither of them significant. The positives all sit lower down. At 300 mg, NREM-2 sleep increased (p = 0.03) and sleep-onset latency shortened (p = 0.004), both ranked secondary in the registration; subjective sleep quality improved (p = 0.005) and the EEG arousal index fell (p = 0.02), both ranked tertiary. The abstract gives these effects for 300 mg and reports no matching 30 mg result.
What it shows: That a single 300 mg dose of CBN changed several measured features of one night's sleep in twenty adults with diagnosed insomnia, and that they rated the night as better.
What it does NOT show: That CBN reduced time spent awake in the night, the objective, sleep-laboratory measure the trial was built around, which held still at both doses. Each participant took each dose once, so repeated use went untested. A night that felt better is a tertiary outcome, and it cannot stand in for the missed primary.
Caveat: Of the three trials, this is the academic one, sponsored by the Woolcock Institute of Medical Research with the University of Sydney as collaborator. Twenty people over three nights logged 247 mild-to-moderate adverse events across the arms, all short of serious, and the authors call for larger and longer trials. The registration also lists next-day simulated driving, postural sway, reaction time and memory consolidation as safety outcomes. The published abstract leaves them out, so next-day function waits on the full text.
What was actually tested: The biggest CBN trial was paid for by the company whose ingredient it tested. It randomised 1,020 participants across five arms, double-blind: TruCBN™, a hemp-derived CBN sleep aid, at 25 mg (n = 206), 50 mg (n = 205) and 100 mg (n = 203), against placebo (n = 204) and 4 mg melatonin (n = 202). The PROMIS Sleep Disturbance 8A questionnaire measured sleep quality, with stress, anxiety, pain and well-being as exploratory measures. The published report names no trial registration, which leaves no public protocol to hold a pre-specified primary endpoint against, and PubMed files it as a journal article where the other two trials are indexed as randomised controlled trials.
All three CBN doses beat placebo on sleep quality, and so did melatonin. The comparison that matters came back null: the paper reports “no significant differences between any group and the melatonin group”, and says again that no treatment group differed from 4 mg melatonin in sleep-quality improvement. Of the exploratory measures, only stress at the 100 mg dose differed from placebo; anxiety, pain, well-being and the frequency of side effects failed to separate from placebo.
What it shows: That 25, 50 and 100 mg of this manufacturer's CBN each improved a self-reported sleep-disturbance score more than placebo did, in a large, blinded, placebo-controlled comparison.
What it does NOT show: That CBN is “as good as melatonin”. Showing two treatments are the same takes a non-inferiority margin set in advance, and this study set none; what it reports is a failure to find a difference from the melatonin arm. A pre-specified benefit of any kind is equally out of reach, because no registered primary endpoint exists to check the analysis against.
Caveat: FloraWorks, which makes the TruCBN™ ingredient, funded the study, and six of the eight authors work for Radicle Science, the contract research organisation that conducted it. The abstract closes by calling orally ingested CBN “a safe and effective alternative for the improvement of sleep”, the sponsor's reading of an unregistered study in which CBN failed to beat the active comparator. How long participants took it, the published abstract leaves unsaid.
Here the story turns on a piece of trial plumbing. Before it starts, a trial names one outcome as the one that will answer its question. Everything else is secondary or tertiary, and a good result further down the list cannot rescue a missed primary. Two of these three trials pre-specified a primary endpoint and missed it. The third never publicly pre-specified one at all. ClinicalTrials.gov keeps the ranking each trial registered, and it repays a look: for the two that missed, the quoted positives sit further down it.
The line that travels is “clinically shown to reduce night-time awakenings”. Awakenings sat in the secondary rank. Sleep quality, the endpoint the trial chose in advance to decide the question, missed significance, and three of the five secondaries were null, among them how long people took to fall asleep.
Registration: NCT05839964. Registered condition: “Healthy Adults”, with healthy volunteers recorded as the enrolled population. No results have been posted. Funding: Canopy Growth Corporation. Every author but one is affiliated with it, and the remaining author is at Wana Brands.
| Registered rank | Pre-specified outcome | What happened |
|---|---|---|
| PrimaryNot met | Median sleep quality rating during the dosing week (Consensus Sleep Diary, completed within an hour of waking each morning) | Not met. 20 mg CBN vs placebo: odds ratio 2.26, 95% CI [0.93, 5.52], p = .082. The confidence interval crosses 1. |
| SecondarySignificant | Number of awakenings after sleep onset | Reduced versus placebo, p = .025. |
| SecondarySignificant | Overall sleep disturbance (PROMIS) | Reduced versus placebo, p = .023. |
| SecondaryNull | Mean latency to sleep onset | No difference from placebo (p > .05). |
| SecondaryNull | Mean time spent awake after sleep onset | No difference from placebo (p > .05). |
| SecondaryNull | Mean daytime fatigue | No difference from placebo (p > .05). |
| Tertiary / otherNot reported | Early-morning awakening; depression, anxiety and stress subscales; irritability; perceived stress; adverse events | Registered as other outcomes, and reported in neither the published abstract nor any posted results. |
The lines that travel are “CBN improved sleep quality in a polysomnography trial” and “CBN cut night-time arousals”, and both come from the tertiary rank. The trial was built to ask whether CBN reduces time spent awake in the night, measured objectively in a sleep laboratory. At 30 mg and at 300 mg, it did not, and a subjective rating cannot make up for a missed objective primary.
Registration: NCT05344170 (acronym: CUPID). Registered as a Phase 1/2 proof-of-concept crossover study in 20 adults with clinician-diagnosed insomnia disorder. Sponsor: Woolcock Institute of Medical Research; collaborator: University of Sydney. Funding: Academic: of the three trials, the one without an industry sponsor.
| Registered rank | Pre-specified outcome | What happened |
|---|---|---|
| PrimaryNot met | Wake after sleep onset (WASO), in minutes, by overnight in-laboratory polysomnography | Not met at either dose. 300 mg: −6.3 min, 95% CI [−18.2, +5.5], p = 0.29. 30 mg: −4.0 min, 95% CI [−15.9, +7.9], p = 0.50. |
| SecondarySignificant | Traditional sleep staging (proportion of the night in wake, N1, N2, N3 and REM) | 300 mg increased NREM-2 sleep, p = 0.03. |
| SecondarySignificant | Sleep onset latency, by polysomnography | 300 mg reduced it, p = 0.004. |
| SecondaryNot reported | Absolute EEG power during NREM sleep | Registered as secondary; absent from the published abstract. |
| Tertiary / otherSignificant | EEG arousal index (registered, in the trial's own words, as a tertiary outcome) | 300 mg reduced it, p = 0.02. |
| Tertiary / otherSignificant | Next-day post-wake subjective sleep evaluation (LSEQ and RCSQ — the registration's only subjective sleep measures, both registered as tertiary outcomes) | 300 mg improved subjective sleep quality, p = 0.005. |
| Tertiary / otherNot reported | Sleep spindles; EEG power in REM; next-day simulated driving, postural sway, reaction time and memory consolidation | Registered as tertiary, exploratory or safety outcomes and absent from the published abstract, which leaves next-day function unreported. |
The line that travels is “as effective as melatonin”. What the paper reports is a failure to detect a difference from melatonin, in a study with no pre-specified non-inferiority margin and no registration: the weakest kind of positive on this page, and the one most often quoted as the strongest.
Registration: None named in the published report. The paper gives no trial-registration identifier, which leaves the protocol unpublished and every analysis unchecked against a pre-specified plan. PubMed indexes it as a journal article rather than a randomised controlled trial. Funding: FloraWorks, the manufacturer of the TruCBN™ ingredient under test. Six of the eight authors work for Radicle Science, the contract research organisation that ran the study.
| Registered rank | Pre-specified outcome | What happened |
|---|---|---|
| PrimaryNot assessable | None publicly pre-specified | Not assessable. Without a registration, the public has no record of what the study set out to measure before it measured it, and that gap hangs over every result it reports. |
| SecondarySignificant | Sleep quality (PROMIS Sleep Disturbance 8A) versus placebo | All three CBN doses and the 4 mg melatonin group improved significantly relative to placebo. |
| SecondaryNull | Sleep quality versus 4 mg melatonin — the active comparator | No significant difference between any group and the melatonin group. Without a pre-specified non-inferiority margin, that reads as a null, short of equivalence. |
| Tertiary / otherSignificant | Stress (exploratory) | 100 mg showed a larger decrease than placebo. |
| Tertiary / otherNull | Anxiety, pain, well-being, and the frequency of side effects (exploratory) | No significant difference from placebo for any of them. |
Put “Sleep quality improved” and “the primary endpoint was sleep quality and it was not significant” in one sentence and one of them wins. The shorter, happier one wins every time. Once the rank is a column, a result can only be quoted alongside the rank it was registered under. That matters most for the two trials that missed their primary, because both also produced positives further down.
The study with the most to say to a formulator was never a CBN trial. It compared six active formulations with each other, without a placebo or a CBN-only arm, so it cannot say what CBN does on its own. What it measures is what CBN adds to a formulation that already works. The largest study in the CBN literature gives a flat answer: nothing measurable changed. For a brand weighing whether CBN earns its place in a sleep blend, it is the nearest the literature comes to testing that exact decision.
What was actually tested: Radicle Science randomised 1,793 adults with sleep disturbance to one of six capsule formulations for four weeks: 15 mg CBD or 5 mg melatonin, each alone or combined with minor cannabinoids including 15 mg CBN and 5 mg CBC. The PROMIS Sleep Disturbance SF 8A tracked sleep disturbance weekly. Every arm was active, with neither a placebo nor CBN on its own, so the improvement inside each group is uncontrolled and the controlled comparisons are the ones between formulations.
For CBN, the answer is null. Adding 15 mg CBN to 15 mg CBD, with or without 5 mg CBC, made no significant difference compared with CBD isolate. Nothing beat 5 mg melatonin, and the melatonin formulations, alone or with CBD and CBN, showed no difference from CBD isolate either. The authors conclude that the effects observed “do not exceed that of 5 mg melatonin” and that “the addition of low doses of CBN and CBC may not improve the effect of formulations containing CBD or melatonin isolate”. Every formulation was well tolerated: 12% of participants reported side effects, none severe.
What it shows: That in the largest study in the CBN literature, adding CBN to a CBD formulation made no measurable difference to a sleep-disturbance score over four weeks.
What it does NOT show: Anything about CBN taken on its own, which no arm tested. Without a placebo, the improvement every group reported cannot be pinned on any product; the controlled comparisons are between formulations, and there the CBN difference fell short of significance.
Caveat: CBN summaries routinely leave this study out, briefs written for us included. The largest study of all found that adding CBN changed nothing, and a summary that lists the three CBN trials while skipping the 1,793-participant null is choosing its evidence.
Then there is the dose. Products marketed for sleep typically contain ≤5 mg of CBN (Corroon 2021). The lowest dose any published trial has used is 15 mg (Saleska 2024), and that arm was a null. Every dose that produced any signal sat between 4× and 60× the retail amount. The figure printed on a typical label sits below everything the sleep trials have tried.
Doses as the studies report them; results and endpoints are in the table below. A tested dose says nothing about a product that contains less.
| Dose | vs retail | Study | What happened |
|---|---|---|---|
| ≤ 5 mg | 1× (the retail dose) | The typical CBN content of products marketed for sleep (Corroon 2021) | Never tested. Every published CBN trial used more, so nothing on this page describes what a ≤5 mg product does. |
| 15 mg, added to 15 mg CBD | 3× | Saleska 2024, n = 1,793, four weeks | No significant difference from CBD isolate alone. The lowest dose anyone has studied also gave the clearest null. |
| 20 mg | 4× | Bonn-Miller 2024, n = 293, seven nights | Primary endpoint (sleep quality) not significant, p = .082. Two secondaries improved; sleep-onset latency, wake after sleep onset and daytime fatigue stayed put. |
| 25 / 50 / 100 mg | 5–20× | Kolobaric 2024, n = 1,020, manufacturer-funded, unregistered | All three doses improved a sleep-disturbance score versus placebo, and none separated from 4 mg melatonin. There is no pre-specified primary endpoint to check. |
| 30 mg | 6× | Lavender 2026, n = 20, one night | Primary endpoint (wake after sleep onset, by polysomnography) not significant, p = 0.50. The abstract gives the significant secondary and tertiary results for 300 mg only. |
| 300 mg | 60× | Lavender 2026, n = 20, one night | Primary endpoint not significant, p = 0.29. Secondary outcomes (NREM-2 sleep, sleep-onset latency) and tertiary outcomes (arousal index, subjective sleep quality) changed significantly. |
The whole CBN sleep story rests on a syllogism: old cannabis feels more sedating, old cannabis has more CBN, so CBN must be the sedative. Nobody has pinned that drowsiness on CBN. Aged material changes in several ways at once, as terpenes evaporate, Δ9-THC degrades and CBN rises, which makes CBN a marker of ageing with no demonstrated role in the effect. The 2021 review that examined the question described the sleep claims as possibly “rooted in cannabis lore” and asked for trials. They were run, at 20 to 300 mg, and the two that pre-specified a primary endpoint missed it.
What was actually tested: A single-author narrative review built around one question: “Is there sufficient clinical evidence to support claims that CBN has sleep-promoting effects?” Of ninety-nine abstracts of studies in people, eight full-text articles met its inclusion criteria. It appeared in August 2021, ahead of all three modern CBN sleep trials; the earliest had not finished dosing.
Corroon judged the CBN literature “dated and limited”: most of the work in people came from the 1970s–1980s, the samples were small, and no clinical trial had yet tied CBN to validated sleep questionnaires or to polysomnography. The conclusion, verbatim, was that there is “insufficient published evidence to support sleep-related claims”. The review asked for randomised controlled trials using polysomnography or validated questionnaires, at doses “significantly higher than those found in currently available cannabis products marketed for sleep (typically ≤5 mg)”. On whether CBN itself produces cannabis-like effects in people, it found the evidence mixed, with most of it showing no such effect.
What it shows: That as of 2021 no clinical trial supported CBN sleep claims, and the point that still holds today: products marketed for sleep typically contain ≤5 mg of CBN, far below any dose anyone had studied.
What it does NOT show: Anything about the three trials that followed it, so it cannot serve as a verdict on Bonn-Miller 2024, Lavender 2026 or Kolobaric 2024. The sequel is instructive. The trials the reviewer asked for were run, at 20–300 mg, and the two that pre-specified a primary endpoint missed it.
The efficacy question has had its trials. The safety question that matters most to a CBN brand has had only mice. CBN and melatonin routinely share a capsule, and the only published evidence on that pairing is a drug-interaction signal in mice, a result that outranks every sleep trial for anyone who makes, sells or takes such a product. Each signal below is tied to the study it came from, and the preclinical ones are marked preclinical.
What was actually tested: Laboratory enzyme work on CYP1A2, the main liver enzyme that clears melatonin, followed by dosing in mice to measure melatonin in the blood. The authors give the commercial reason for the study themselves: products combining CBN with melatonin are widely sold, and cannabinoids are known to inhibit drug-metabolising enzymes.
In the laboratory assay, CBN potently inhibited the CYP1A2-mediated metabolism of melatonin. In mice it increased melatonin's apparent oral bioavailability, producing a four-fold increase in plasma melatonin exposure. The authors frame it as one more example of a potential drug–drug interaction involving melatonin.
What it shows: That CBN can block the enzyme that clears melatonin, and that in an animal this raises how much melatonin reaches the bloodstream from the same dose.
What it does NOT show: What happens in a person. No CBN–melatonin interaction study in people has been published, so the size of this effect at a human dose is unknown, and the paper settles neither the case for danger nor the case for safety. What it does justify is a word with a prescriber or pharmacist before treating a CBN-plus-melatonin product as two ingredients that simply add up.
Caveat: Mice are a long way from people, but the combination is already on shelves in a single capsule, which is why a preclinical finding matters here. A summary that cites CBN's sleep trials and leaves this paper out tells the half of the story a seller prefers.
CBN and melatonin routinely share a capsule. In the laboratory, CBN strongly inhibited CYP1A2, the enzyme that clears melatonin, and in mice it raised melatonin exposure in the blood roughly four-fold (Anderson 2025, PMID 39722474). The work is preclinical, cells and mice alone, and no interaction study in people has been published, so the size of the effect in a person is unknown. Reason enough to raise a CBN product with a pharmacist rather than assume the combination is inert.
Twenty participants, dosed on three separate nights in the polysomnography trial, logged 247 mild-to-moderate adverse events across its three arms (Lavender 2026, PMID 41698831). None was serious, which makes this a tolerability signal rather than a safety alarm. Still, it is a lot of events for a trial whose primary endpoint came back null, and its authors call for larger and longer studies.
The manufacturer-funded study found no significant difference in side-effect frequency between any CBN dose and placebo (Kolobaric 2024, PMID 39204082). In the 1,793-participant formulation study, 12% of participants reported side effects and none were severe (Saleska 2024, PMID 37162192). Both studies were short, self-reported and industry-run, so the reassurance holds at that scale and duration, but it is not a characterised safety profile.
The trials that gave CBN on its own lasted seven nights (Bonn-Miller 2024) and a single night per dose (Lavender 2026). The four-week exposure came with CBN inside a CBD formulation (Saleska 2024), and the Kolobaric 2024 abstract leaves its dosing duration unstated. Months of use remain unstudied.
CYP2C9 and CYP3A4, the enzymes that do most of the work on CBN in human liver preparations (Watanabe 2007, PMID 17303175), also handle a great many prescription medicines. That overlap makes cannabinoid–medicine interactions plausible, and no CBN interaction study in people has been published. If you take prescription medicines, discuss any cannabinoid product with your prescriber or pharmacist.
A 1984 study usually gets quoted for one result: CBN lowered eye pressure in cats. The other half is toxicity. The same cats developed conjunctival redness and hyperaemia, and rats given CBN systemically showed polyspike discharges on the electrocorticogram. Cannabigerol, tested alongside it in the same paper, lowered eye pressure without either effect (Colasanti 1984, PMID 6499952). Four decades old and confined to animals, the toxicity half still belongs in any summary that quotes the eye-pressure half.
Because CBN is formed from THC, residual THC is a fair question to put to any CBN product's certificate of analysis. Nobody has measured it in CBN products specifically, so the nearest evidence is an analogy. In an Argentine survey of 500 commercial cannabis oils, 13 of the 17 products labelled “THC-free” tested positive for Δ9-THC, which is 76.5% of a very small subgroup (Fernández 2023, PMID 37392612). Those were cannabis oils, and the figure rests on seventeen items: grounds for a labelling caution, and for nothing about any specific product.
CBN has no approved use in any jurisdiction and is not a treatment for insomnia or any other sleep disorder. Nothing here diagnoses, treats, cures or prevents any disease, and nothing here is a recommendation to take CBN or a dose at which to take it. Do not change or stop a prescribed sleep medication because of this page. Persistent sleep problems are worth raising with a clinician, since they can have causes a supplement will not address. If you take prescription medicines, melatonin included, discuss any cannabinoid product with your prescriber or pharmacist. See safety & reporting and how we grade.
Trials ask whether something works; lab and animal studies can only suggest how. Keep the two apart, because merging a receptor result with a clinical outcome is how a lab finding turns into a health claim on a label. Switch to Researcher depth for the cited mechanism record.
The animal work tells a stranger story than the label. In rats, CBN does change objectively measured sleep, but sleep is suppressed first and increases only later, a pattern “sedating” fails to describe. The researchers also found that most of the cannabinoid-receptor activity after a CBN dose comes from a compound the body makes from CBN, rather than from CBN itself. All of it is rat work, set against human trials that missed their primary endpoints. Switch to Researcher depth for the cited detail.
What was actually tested: Polysomnography in rats, with brain and plasma concentrations measured, plus cannabinoid-receptor assays. Rodents throughout.
CBN increased total sleep time in rats, raising both non-REM and REM sleep, but it got there by a biphasic route, with a spell of sleep suppression before the increase. After a CBN dose, its metabolite 11-hydroxy-CBN reached brain concentrations comparable to CBN itself, and the receptor assays measured its activity directly. 11-hydroxy-CBN was active at cannabinoid CB1 receptors with potency and efficacy comparable to Δ9-THC, while CBN itself had much lower activity. The metabolite also influenced sleep architecture, with some differences from CBN. On non-REM sleep, CBN's effect was comparable in size to the sleep aid zolpidem, though zolpidem left REM sleep alone and CBN changed it.
What it shows: That in rats CBN changes objectively measured sleep architecture, that the change is biphasic rather than simple sedation, and that a metabolite of CBN carries most of the CB1 activity, with CBN itself much weaker.
What it does NOT show: Anything about people. The zolpidem comparison is a rat measurement and does not mean CBN performs like a prescription hypnotic in a person; the trials that tested CBN for sleep in people missed their primary endpoints. Nor does it show that people handle the metabolite the way rats do. Watanabe 2007 shows human liver enzymes form 11-hydroxy-CBN, but its brain exposure and effects in a person have never been measured, and joining the two studies is an inference across species.
Caveat: “CBN increases total sleep time in rats” is true and incomplete, because it drops the initial sleep suppression. For a compound sold to be taken at bedtime, an early sleep-suppressing phase in an animal model is exactly the detail a summary should keep.
What was actually tested: Human hepatic microsomes and recombinant human cytochrome P450 enzymes, in the test tube: human tissue with no human participants, which sets the study apart from the trials in people.
CBN was metabolised mainly to 11-hydroxy-CBN and 8-hydroxy-CBN. CYP2C9 principally catalysed the 11-hydroxylation and CYP3A4 the 8-hydroxylation, and selective inhibitors of each enzyme family blocked the corresponding reaction. The paper's catalytic rate figures stay with the paper.
What it shows: That human liver enzymes convert CBN into 11-hydroxy-CBN, and which two enzymes do most of the work, which is the human-tissue basis for expecting CBN to interact with medicines handled by CYP2C9 and CYP3A4.
What it does NOT show: What that metabolite then does in a person. The study measures formation alone, leaving effect, brain exposure and behaviour unmeasured, and the metabolite's CB1 activity comparison comes solely from the rat work.
What was actually tested: A review of the molecular pharmacology of the seven most thoroughly investigated phytocannabinoids (Δ9-THC, Δ9-THCV, cannabinol, cannabidiol, cannabidivarin, cannabigerol and cannabichromene), covering targets inside and outside the endocannabinoid system. As a secondary source, it reports other people's experiments.
CBN is one of the seven compounds characterised, but the review earns its place for one line of framing: “slight structural differences can elicit diverse and competing physiological effects”. CBN arises from THC, and it still cannot be treated as a milder THC.
What it shows: That CBN has been characterised pharmacologically alongside the other major phytocannabinoids, and that structural similarity between cannabinoids does not imply similar effects.
What it does NOT show: Any clinical effect. A molecular-pharmacology review describes what a compound binds and modulates in laboratory systems, and this one predates every CBN sleep trial as well.
Caveat: Secondary source. Its binding constants are specialist figures and stay in the original.
Set the first two records side by side and a tidy conclusion suggests itself. Human liver enzymes form 11-hydroxy-CBN (Watanabe 2007). In rats, that metabolite reaches high brain concentrations and is active at CB1 comparably to Δ9-THC (Arnold 2025). So a person taking CBN might be making a THC-like agent in the brain. Nobody has measured that. One study measured formation in human liver tissue; the other measured brain exposure and receptor activity in rats. Joining them is an inference across species, worth holding as exactly that. What the assays did measure is that CBN itself had much lower CB1 activity than its metabolite, which is also why CBN cannot be treated as a milder THC, a point the 2017 review makes directly.
Away from the bedside table, CBN has a second literature on eye pressure and the retina, all of it preclinical. One of the studies delivered CBN by injection straight into the eye, and the older one reports a toxicity finding that has a habit of going missing whenever its eye-pressure result is quoted.
What was actually tested: Mouse retinal ganglion precursor-like cells under elevated hydrostatic pressure, human trabecular meshwork cells, and a rat model of glaucoma made by laser photocoagulation of the episcleral vein. CBN went in by intravitreal injection, directly into the eye, a route not comparable to swallowing a capsule and one no consumer product uses.
CBN protected the cultured cells from pressure-induced toxicity in a dose-dependent way and reduced changes in extracellular-matrix proteins in the trabecular meshwork cells. Injected into the eye in the rat model, it improved pattern electroretinogram amplitudes and lowered intraocular pressure.
What it shows: A preclinical, multi-target signal for CBN in eye tissue and in a rodent glaucoma model, with CBN injected directly into the eye.
What it does NOT show: Any clinical effect in glaucoma. No trial has tested CBN in people with glaucoma, and this study cannot stand in for one. Glaucoma causes irreversible vision loss and is managed by an ophthalmologist. Nothing here is a treatment, and no CBN product should be used in place of prescribed care.
Caveat: Three authors are affiliated with InMed Pharmaceuticals, and the paper prints that affiliation. The company's cannabinol eye programme, INM-088, goes unnamed in the paper, so we leave the two unlinked: reporting an affiliation is fair, and attaching a development programme the paper never mentions would be inventing a fact.
What was actually tested: In cats, cannabinol or cannabigerol was applied to the eye as a single topical drop or delivered continuously for nine days by osmotic minipump. In rats, either compound was given systemically with electrocorticogram recording. Animals only.
Both compounds lowered intraocular pressure in cats, more so on chronic dosing, and cannabigerol's chronic response was the larger of the two. The toxicity results, the ones usually left out, split the pair. Cannabinol caused conjunctival redness and hyperaemia, and cannabigerol caused neither. Systemic cannabinol also produced 8–13 Hz polyspike discharges on the rat electrocorticogram during wakefulness and REM sleep, which cannabigerol did not. The authors conclude that cannabinol, like cannabis and Δ9-THC, produced both ocular and neurotoxicity, while cannabigerol's pressure-lowering effect appeared dissociable from those adverse effects.
What it shows: That in animals, four decades ago, both compounds lowered eye pressure, and that in the same experiments CBN produced two adverse effects that CBG did not.
What it does NOT show: Anything about people, or about treatment. Its eye-pressure results circulate on their own; the toxicity results sit in the same abstract and belong beside them.
Four stories keep circulating as CBN evidence, and each comes back however often it is knocked down. Here are the reasons to leave them out, ready for the next time one turns up in a sales deck.
The ratio recurs across cannabis writing, and every trail we followed ran out before reaching a primary source that measures it. The 1996 receptor-binding paper it is usually credited to characterises binding at the CB2 receptor and gives no CB1 potency ratio. We leave that paper's identifier out as well, since citing it just to knock the claim down would put a real identifier next to a claim it does not support. What has been measured is narrower: in rats, CBN itself had much lower CB1 activity than its metabolite, which was comparable to Δ9-THC (Arnold 2025).
A 2021 randomised crossover trial of the sublingual cannabinoid medicine ZTL-101 improved insomnia symptoms in 23 of 24 participants over two weeks (Walsh 2021, PMID 34115851). But ZTL-101 is a multi-cannabinoid extract, and nothing in the trial's design, from its arms to its comparisons, isolates what CBN contributed, so it supports no CBN claim. Its milligram composition is missing from the published abstract as well. A positive trial of a mixture is evidence about the mixture.
Folklore, and the seed of the whole CBN sleep story. The 2021 review that examined the question describes the sleep claims as possibly “rooted in cannabis lore” (Corroon 2021, PMID 34468204), and no study has attributed the drowsiness of aged cannabis to CBN. Aged material differs from fresh in many ways at once: terpenes evaporate and THC degrades. Rising CBN is a marker of that ageing, and a marker is all it has been shown to be.
The nearest published evidence is a survey of commercial cannabis oils, which works as an analogy only with its denominator attached: 13 of 17 products labelled “THC-free” tested THC-positive (Fernández 2023, PMID 37392612). Dressed up as a CBN finding, or quoted as 76.5% without its seventeen-item base, it would pin a false fact to a real citation.
Put CBN beside two cannabinoids the plant makes on purpose and the odd one out is obvious. CBG and CBDV stand in as reference chemistry, and their records stay in their own columns.
| Property | CBG (made by the plant) | CBDV (made by the plant) | CBN (a degradation product) |
|---|---|---|---|
| Where it comes from | Made by the plant. CBGA is the mother acid; heat removes CO₂ to give neutral CBG. | Made by the plant, on the varin branch. CBDA synthase converts CBGVA to CBDVA, which decarboxylates to CBDV. | Made by oxidation rather than by the plant's enzymes. CBN appears as Δ9-THC and THCA oxidise with air, light and time. |
| Is there a dedicated enzyme? | Yes. CBGA is the substrate the three branch synthases compete for. | Yes. CBDA synthase, characterised for the pentyl reaction and inferred for the varin one. | No. There is no CBN synthase. CBN forms through oxidation and heat. |
| Molecular formula | C₂₁H₃₂O₂ · ≈ 316.48 g/mol | C₁₉H₂₆O₂ · ≈ 286.4 g/mol | C₂₁H₂₆O₂ · ≈ 310.43 g/mol, six hydrogens lighter than CBG because it is oxidised |
| What its level on a certificate of analysis tells you | Chemotype and harvest timing: how much the plant made, and how much converted onward. | Chemotype: whether the plant runs the propyl branch at all. | Age and storage. It works more like a freshness measurement than a cultivar one. |
| The caution that travels with it | Blood pressure — CBG is an α2-adrenoceptor agonist, so a cardiovascular caution travels with it wherever its effects are discussed. | Liver enzymes — transaminase elevations appeared in two independent CBDV studies. | Melatonin. CBN inhibited the enzyme that clears melatonin and raised melatonin exposure four-fold in mice, and the two are sold in the same capsule. |
| Trials in people | See the CBG monograph, the most thoroughly graded record on this site. | Four published, including a Phase 2 randomised controlled trial in focal epilepsy. None met a primary efficacy endpoint. | Three, all testing CBN for sleep. Both that pre-specified a primary endpoint missed it, and the third names no registration. |
| What it was tested for | A range of indications. See the monograph and the gap map. | Seizures, HIV-associated neuropathic pain, and autism-related brain imaging. | Sleep, and almost nothing else: every modern trial of CBN in people is a sleep trial. |
| Approved medicine | None. | None, in any jurisdiction. | None, in any jurisdiction, as a hypnotic or for anything else. |
| The characteristic misreading | That a precursor's importance to the plant transfers to a person. | That CBDV inherits CBD's clinical standing because the names and scaffolds are close. | That “the sleep cannabinoid” has a sleep indication behind it, and that a positive secondary or tertiary result counts the same as the primary endpoint. |
| Does the neighbouring column transfer? | NO. | NO. | NO. Being a cannabinoid is a structural fact, and evidence stays with the compound it was gathered on. CBN's own record is the sleep record. |
Each of the three has a record built from its own studies. CBN's comes down to the sleep work: three trials, two missed primaries, one unregistered positive that failed to separate from 4 mg melatonin (Kolobaric 2024), and a 1,793-participant null (Saleska 2024). That is all of it, and thin as it sounds, it is still more than most minor cannabinoids can show.
Once the trials have had their say, buyers and consumers ask more practical things: legality, product formats, drug testing, buying and labelling. Identity and chemistry get stated as fact, with a grade. Claims about sleep, sedation and relaxation are reported as other people's claims and are not endorsed here.
Of the 50, 33 carry a verified grade on the six-rung evidence ladder. 17 carry an evidence state instead of a rung, most often no primary evidence, meaning our registry is silent on the question, a different verdict from not supported, where the evidence weighs against a claim.
The questions and answers below were written before the modern CBN sleep trials were added here, and several answers still describe controlled sleep and dosing studies in people as lacking or absent. That is out of date. Three such trials are set out in full above, with their pre-specified endpoints and results, and where the two disagree the evidence sections above take precedence. The answers come from a generated source file this page does not own, and the corrections have been filed for its next regeneration, since hand-editing a generated corpus would stop it from regenerating cleanly.
Cannabinol (CBN) is what THC turns into as it ages: a minor, non-intoxicating cannabinoid in cannabis and hemp, and THC's oxidative breakdown product. Fresh plants hold only traces. CBN builds up in older material and in material left in heat or light, so a high CBN reading on a batch says something about how it was stored.
"Cannabinol" is the common name of one specific molecule, among the first cannabinoids ever isolated from cannabis. "Cannabi" marks it as a cannabinoid, and the "-ol" ending reflects its chemistry. Today the name belongs to the aromatic compound that forms when THC oxidises with age.
Essentially, yes: CBN is the oxidative degradation product of THC. Oxygen, heat, light and time slowly convert THC to CBN, so aged or badly stored cannabis carries more CBN than fresh flower, which holds only trace amounts.
Natural. CBN forms in the plant as THC ages and oxidises, without any lab step. Commercial CBN may be extracted from aged hemp or made by oxidising THC under controlled conditions, and either way the molecule is the same natural degradation product.
Not the way THC does. CBN is considered non-intoxicating or, at most, weakly intoxicating, well short of THC's characteristic high, and its activity at cannabinoid receptors is weak. Some people report mild relaxation, but CBN is not classed as a strongly psychoactive cannabinoid.
CBN is generally classed as non-intoxicating or, at most, weakly intoxicating, and "psychoactive" is a wider word than "intoxicating". It stops well short of THC's high. In laboratory studies its activity at cannabinoid receptors is weak, and any subjective mental effects in people are mild and poorly characterised.
No trial has measured whether CBN is sedating. CBN is widely sold as "sedating", and some users say it makes them drowsy, yet the three controlled trials that have given CBN to people all left sedation off their outcome lists, and one found next-day fatigue no different from placebo (Bonn-Miller 2024). The reputation may owe more to aged cannabis than to CBN, and individual experiences vary. (Not medical advice.)
No trial has ranked them. Relaxation has not been a pre-specified outcome in any CBN trial, and when CBD was added to CBN it changed nothing on the sleep measures tested (Bonn-Miller 2024). A product claiming one relaxes more than the other is making a marketing claim rather than reporting a measured comparison. (Not medical advice.)
Generally yes in the US, with state exceptions. As of 2026, hemp-derived CBN is federally legal in the United States under the 2018 Farm Bill when the product contains at most 0.3% delta-9 THC by dry weight. State laws vary and the rules keep changing. General information, not legal advice; check local rules.
Generally yes. The 2018 Farm Bill legalized hemp and hemp derivatives containing at most 0.3% delta-9 THC by dry weight, and that is usually read to cover hemp-derived CBN. Shifting "total-THC" interpretations add some uncertainty. As of 2026; general information, not legal advice.
That depends on the state. Some restrict or ban hemp-derived cannabinoids even where federal rules allow them, and the map moves often enough that your state's current law is the only reliable guide. Check it, or ask a qualified attorney. As of 2026; general information, not legal advice.
Each runs its own cannabis and novel-food law, and the US Farm Bill stops at the border. Canada regulates CBN under the Cannabis Act. The UK and EU handle cannabinoids through controlled-substance and novel-food frameworks, and neither has specifically authorised CBN as a food. Status varies and changes; general information, not legal advice.
No benefit of CBN has been established in people. In the lab it is a potent TRPA1 agonist and desensitiser, and it shows antibacterial activity, including against MRSA, in vitro (De Petrocellis 2011; Appendino 2008). The benefit it is actually sold on, sleep, has been tested in people, and both trials that pre-specified a primary endpoint missed it (Bonn-Miller 2024; Lavender 2026). CBN holds no approved use in any jurisdiction. (Not medical advice.)
Mostly for selling sleep. CBN goes into "sleep" and relaxation products, often blended with melatonin, CBD or other cannabinoids, and those are marketing uses. It lacks any approved therapeutic indication, and the sleep claim has been through controlled trials that missed their pre-specified primary endpoints, which leaves any CBN sleep claim on a label arguing with the trial record. (Not medical advice.)
Not on the evidence so far. CBN has been tested for sleep in people, and the trials missed the endpoints they set in advance. In 293 self-rated poor sleepers, 20 mg nightly for a week failed to improve sleep quality significantly (Bonn-Miller 2024). In a sleep laboratory, 30 mg and 300 mg failed to shorten the time spent awake at night (Lavender 2026). Some lower-ranked outcomes did move, and those are a poor substitute for a missed primary endpoint. (Not medical advice.)
Yes. Three published trials have given CBN to people for sleep, at 20 mg, at 25/50/100 mg, and at 30 mg and 300 mg (Bonn-Miller 2024; Kolobaric 2024; Lavender 2026). Both trials that registered a primary endpoint missed it, and the third lacks a registration altogether. So the human evidence exists, and where the outcome was set in advance, it points against the claim.
Short-term safety has been measured in trials; long-term safety has not. Side-effect frequency in a 1,020-person study was no different from placebo (Kolobaric 2024), while a 20-person laboratory trial recorded 247 mild-to-moderate adverse events across its arms, none serious (Lavender 2026). No long-term safety study or human interaction study has been published. Consult a qualified professional before use, especially if pregnant, nursing or on medication. (Not medical advice.)
Grogginess has been measured: on 20 mg, next-day fatigue came out no different from placebo (Bonn-Miller 2024). A single-night laboratory trial at 30 mg and 300 mg recorded 247 mild-to-moderate adverse events, none serious (Lavender 2026). Many "sleep" products also contain melatonin or other cannabinoids, so an effect may not come from CBN alone. Stop use if you feel unwell. (Not medical advice.)
Nobody has defined a safe dose or toxicity threshold for CBN in humans, so there is no reliable "safe maximum," and we give no dosing guidance. Trials have used single doses as high as 300 mg and nightly doses of 20 to 100 mg; those are research doses, set down for the record rather than offered as amounts to take. More is not better; consult a qualified healthcare professional. (Not medical advice.)
No interaction study in people has been published. In human liver preparations, CBN is processed by major drug-metabolising enzymes (Watanabe 2007). In mice, it blocked the enzyme that clears melatonin and raised melatonin exposure about four-fold (Anderson 2025). The finding is preclinical, and it lands awkwardly for an industry that routinely sells CBN and melatonin in the same capsule. Talk with your doctor or pharmacist before combining products. (Not medical advice.)
Possibly, and the risk is real. Standard tests screen for THC and its metabolites, and because CBN is a chemical relative of THC, it can cross-react with some immunoassay tests and could produce a positive result. CBN products may also carry trace THC. Anyone who is tested should weigh that before use.
Pure CBN contains no THC; it is a separate molecule, the oxidation product of THC. Because CBN forms from THC in cannabis and hemp, though, CBN products can carry trace residual THC and other cannabinoids, so check the product's third-party lab report.
Yes, the risk is real, and it has two sources. CBN can cross-react with the THC immunoassays used in standard screening, and CBN products can carry trace THC that the tests are built to detect. No study has measured residual THC in CBN products specifically, so the second route is plausible rather than quantified. Anyone subject to drug testing is safest avoiding CBN products.
All three are common. CBN comes as oils and tinctures held under the tongue, gummies and other edibles, and capsules, often blended with melatonin, CBD or other cannabinoids in "sleep" formulas. The route changes how quickly effects start and how long they last. How much to take is a separate question, and we give no dosing advice.
Oils and tinctures, gummies and edibles, capsules or softgels, and vape products, frequently sold as "sleep" blends with melatonin, CBD or terpenes. Purity and actual CBN content swing widely, so the third-party lab report matters. We don't endorse any brand.
No CBN dose has been established or clinically validated, for sleep or anything else, and dosing recommendations are outside what we do. Controlled trials have tried 20 mg, 25 to 100 mg, and 30 to 300 mg, and none met a pre-specified primary endpoint for sleep. The 5 mg or less typical of retail products has never been tested at all. Discuss any use with a qualified healthcare professional. (Not medical advice.)
No evidence-based timing exists. The trials dosed CBN nightly for a week and as single doses in a sleep laboratory, without comparing timings, and CBN's pharmacokinetics in people are unpublished. Onset and duration also depend on format (edibles act more slowly than sublingual oils) and vary by person. We give no dosing or timing guidance. (Not medical advice.)
Neither has been shown better. CBN's own sleep trials missed their pre-specified primary endpoints, and in the largest study of any CBN formulation, with 1,793 people, adding 15 mg CBN to 15 mg CBD made no difference compared with CBD alone (Saleska 2024). No published trial has compared CBN alone with CBD alone. The molecules also differ in origin: CBN forms as THC degrades, while the plant makes CBD. (Not medical advice.)
CBN is what THC becomes as it ages and oxidises, and the practical difference is intoxication. THC is strongly intoxicating, while cannabis-like effects from CBN have been mixed and mostly unobserved in people (Corroon 2021). Think of CBN as a chemically different, fully aromatised molecule that shares THC's origin, rather than a milder THC.
They share little beyond being non-intoxicating minor cannabinoids. The plant builds CBG from CBGA, the "mother" cannabinoid, while CBN forms as THC degrades, without a dedicated enzyme. In vitro they act at different receptor targets. Neither has an established human sleep benefit, and for CBN that verdict comes from trials.
CBN has been compared with melatonin twice and came out no better either time. Against 4 mg melatonin, no CBN dose (25, 50 or 100 mg) differed significantly from the melatonin group (Kolobaric 2024), and in a 1,793-person study nothing beat 5 mg melatonin (Saleska 2024). A non-significant difference falls short of equivalence, so a label promising "as good as melatonin" is unsupported too. (Not medical advice.)
CBN's molecular formula is C₂₁H₂₆O₂, and its molecular weight is about 310.43 g/mol (CAS 521-35-7; PubChem CID 2543). CBN is the fully aromatic, oxidised relative of THC, and that extra oxidation and aromatisation are exactly what separate the two.
Yes, given time. Oxygen, heat and light oxidise and aromatise THC into CBN. Most cannabinoids are built from CBGA by a plant enzyme; CBN is a degradation product instead, which is why aged cannabis accumulates it.
Yes, and the fact defines it. CBN is the oxidative degradation (breakdown) product of THC, forming as THC ages with exposure to oxygen, heat and light. Where most cannabinoids have a dedicated plant enzyme, CBN simply accumulates as fresh, THC-rich material gets older.
Only partly. A cannabinolic acid (CBNA) does exist: it arises as THCA oxidises with age and can decarboxylate to CBN. CBD and THC come mainly from CBGA-derived acids made by synthases, but CBN's defining route is the oxidation of neutral THC, so at root it is a degradation product.
Online from hemp and cannabinoid retailers and, where legal, in dispensaries and specialty stores, usually as "sleep" oils, gummies or capsules. Availability depends on local law (see the legality answers). Quality varies, so buy only from sellers who provide third-party lab testing. We don't endorse vendors.
Because fresh cannabis contains only trace CBN, which builds up slowly as THC degrades. Producing it takes aged material or controlled oxidation of THC, then extraction and purification. Low natural abundance and the extra processing make CBN scarcer and costlier than mainstream cannabinoids such as CBD.
Ask for a current Certificate of Analysis (COA) from an independent third-party lab. It should confirm that the CBN content matches the label, report THC levels (which matter for drug tests and legality), and screen for contaminants such as pesticides, solvents and heavy metals. A product sold without a COA is a red flag.
Your call, but know what the trials found. CBN's headline selling point, better sleep, has been tested, and the pre-specified primary endpoints were missed. No dose has been shown to meet one, the 5 mg or less typical of retail products has never been tested, and CBN can affect drug tests. Discuss it with a qualified healthcare professional first. (Not medical advice.)
Transparency first: a recent third-party COA that verifies CBN content and screens for contaminants, clear labelling of every cannabinoid amount including any THC, and a seller you can identify and contact. Check that the product is legal where you live, and be wary of sleep claims that run ahead of the evidence.
Many sleep products combine them, and the pairing has been tested, and the benefit failed to show up either way round. Adding CBN to CBD made no difference compared with CBD alone (Saleska 2024), and in a placebo-controlled trial, adding CBD to CBN improved nothing (Bonn-Miller 2024). Combined cannabinoids may still add to drowsiness, so avoid driving, and ask a clinician if you take other medicines. (Not medical advice.)
A reliable figure is still missing. CBN is fat-soluble like other cannabinoids and may linger, but human data on how long it can be detected are lacking. For testing, the bigger point is that CBN can cross-react with THC immunoassays and products may contain trace THC, a real positive-test risk.
Unknown; nobody has studied whether repeated CBN use builds tolerance in humans, and the headline sleep claim, when tested in people, came back unsupported. If a product seems to stop working, reassess with a clinician rather than taking more. (Not medical advice.)
No evidence shows CBN is addictive. CBN is non-intoxicating or at most weakly intoxicating, with only weak activity at cannabinoid receptors in the lab, unlike intoxicating THC. Its abuse liability has not been formally studied in humans, though, and a sleep-marketed product used nightly deserves a doctor's input. (Not medical advice.)
Probably not because of CBN. Aged cannabis does accumulate CBN as THC degrades, which is how CBN earned its "sleepy" reputation, but when its sleep claim went to trial in people, the endpoints set in advance were missed (Bonn-Miller 2024; Lavender 2026). Whatever else in old cannabis might cause drowsiness remains unidentified. (Not medical advice.)
CBN's effect on pain has not been established in controlled human studies. Some manufacturers market it for pain or physical discomfort, and preliminary preclinical work has looked at cannabinoids and pain pathways in general. CBN lacks any approved use for pain, and the claim belongs to the sellers who make it. (Not medical advice.)
Be cautious. CBN is sold as sedating and some users report drowsiness, so it could impair driving even in the absence of a clear "high", and CBN products may contain trace THC. Sedation and other cannabinoid effects vary by person and product; if you feel any drowsiness or effect, leave the car and the machinery alone. (Not medical advice.)
It cannot be called safe for pets. Veterinary data on CBN are very limited, animals can be more sensitive than people, and products may contain trace THC, which is toxic to dogs. Ask a veterinarian before giving any cannabinoid to an animal. (Not medical advice.)
Avoiding it is the safest course. The FDA strongly advises against using CBD, THC or marijuana in any form while pregnant or breastfeeding, and CBN's safety in pregnancy has not been established. Speak with an obstetrician or midwife before using any cannabinoid product. (Not medical advice.) CBN products can also contain trace THC.
Nobody has studied the combination, so it cannot be called safe. Alcohol and sedative-marketed CBN can both cause drowsiness, and their combined effect on alertness or coordination is unpredictable. Stay off the road after combining them, go slowly, and ask a clinician or pharmacist, especially if you take other medication. (Not medical advice.)
Each of these needs a new study. When one is published, it goes through our registry and comes out graded and cited.
The shortest route off a null is a registered trial, in a defined population, that meets the primary endpoint it set in advance. Two of the three CBN sleep trials set one and missed it, and the third named no registration at all. Until a trial clears that bar, the evidence supports no sleep claim at any dose.
Every dose that produced any signal is 4–60× the ≤5 mg typical of products marketed for sleep, and the closest anyone has come to a retail dose, 15 mg inside a CBD formulation, was a null. Nobody has tested what is on the shelf, and until someone does, the trial record is not evidence about the product in a buyer's hand.
Industry wrote two of the three trials, and the largest positive was funded by the maker of the ingredient it tested and run by a contract research organisation. Independent, registered replication would settle far more than another sponsor study. Beyond that, two measurements in people would each outweigh another questionnaire. One is pharmacokinetics for CBN and its 11-hydroxy metabolite, because rodent brain concentrations cannot tell us a person's exposure. The other is a study of the CBN–melatonin interaction, a mass-market pairing whose evidence so far comes from mice alone.
The CBN-specific papers in one place, with PubMed and DOI links for anyone who wants to check the reading. All of them stay ungraded here, because no CBN study has entered our registry yet.
Randomised, placebo-controlled · in people · primary endpoint missed
Crossover · polysomnography · in people · primary endpoint missed
In people · n = 1,020 · manufacturer-funded · unregistered · not indexed as an RCT
n = 1,793 · six active arms · no placebo · formulation null for CBN
Narrative review · published 2021, before all three CBN sleep trials
Preclinical · liver enzymes in vitro + mice · not people
Preclinical · rat polysomnography + receptor assays · not people
In vitro · human liver microsomes and recombinant enzymes
Review · secondary source · molecular pharmacology
Preclinical · cells + rats · intravitreal delivery only
Preclinical · cats and rats · 1984
Walsh 2021. “Treating insomnia symptoms with medicinal cannabis: a randomized, crossover trial of the efficacy of a cannabinoid medicine compared with placebo”, Sleep 2021;44(11):zsab149, PMID 34115851, doi:10.1093/sleep/zsab149; a trial of the multi-cannabinoid extract ZTL-101, without a CBN-only arm or a CBN comparison, so it sits outside the CBN evidence entirely.
Fernández 2023. “An assessment of qualitative and quantitative cannabinoids analysis in selected commercially available cannabis oils in Argentina”, Forensic Science International 2023;349:111762, PMID 37392612, doi:10.1016/j.forsciint.2023.111762; it analysed cannabis oils rather than CBN products, and appears only as a labelling analogy, with its denominator (13 of 17) attached.
For the compound with our deepest graded record, see the CBG monograph; for the other Atlas pillar whose trials missed their primary endpoints, see CBDV; and for how a claim earns a rung, see how we grade.
CBN (cannabinol) is the most heavily marketed cannabinoid the site covers, and the most consumer-relevant finding in the cannabinoid safety literature right now concerns a CBN product combination on shelves today. Nothing in this section describes CBG or CBDV; their cautions live on the safety page.
CBN is not made from CBG, and it is not a plant product in the way the others are. There is no CBN synthase. The plant sends CBGA down three enzymes that end at THC, CBD and CBC, and none of them makes CBN. CBN turns up afterwards, as Δ9-THC and THCA oxidise with exposure to air, heat, light and time. It builds up in aged and poorly stored material, so a CBN reading says more about freshness than about cultivar. All of that is settled chemistry rather than a finding.
Coming from THC transfers nothing. THC's effects, THC's legal status and THC's clinical record belong to THC; a molecule is its own thing, whatever it was made from. Descent from an intoxicant is evidence neither that CBN is intoxicating nor that it is mild. What counts is CBN's own record, set out below.
CBG's and CBDV's records do not transfer either. The α2-adrenoceptor blood-pressure note on the safety page is a CBG finding and says nothing about CBN. The food-effect finding on the safety page comes from a CBG study and does not extend to CBN. The liver-enzyme signal in the CBDV safety section is CBDV's, from different studies in different people.
Here is that combination. CBN + melatonin is a mass-market retail combination: the two routinely share a single sleep capsule or gummy, which makes the finding about a product pairing rather than a compound on its own. A 2025 study asked what happens when they are taken together.
It found that CBN potently inhibits CYP1A2, the main liver enzyme that clears melatonin, and that giving CBN with melatonin to mice produced a roughly four-fold increase in melatonin exposure in the blood. The same group had earlier reported CBN inhibiting the same enzyme's handling of caffeine. In practice, the mechanism suggests that the melatonin dose printed on a combination product may not match the melatonin exposure it delivers. (Anderson et al., 2025, Basic Clin Pharmacol Toxicol 136(1):e14120, PMID 39722474, doi:10.1111/bcpt.14120.)
Now the limit, which matters as much as the finding. The evidence is laboratory enzyme assays and mice, and not a demonstrated interaction in a person. No CBN drug-interaction study in people has been published, so whether this happens in a human, and how large it would be, is unknown. That gap is no reassurance. The combination is already on sale, and nobody has measured the interaction in the people buying it; that is why a preclinical study leads this section. If you take a CBN + melatonin product, or take CBN alongside any medicine with a narrow safe range, a pharmacist can check your specific list against CYP1A2. A reference page cannot, and should not try.
Verified against its PubMed record and cited in prose. The paper has yet to become a graded entry in the CBG Atlas registry, so it stays ungraded here, and a preclinical finding could not ground a human interaction grade in any case. The inhibition strength stays in the paper.
Start with the endpoints, because the rest cannot be read without them. Both CBN sleep trials that pre-specified a primary endpoint missed it. In a randomised placebo-controlled trial of 293 adults taking 20 mg nightly for seven nights (Bonn-Miller et al., 2024), the primary endpoint was sleep quality, and it was not significant (p = .082). Two secondary measures were significant: fewer nighttime awakenings (p = .025) and lower overall sleep disturbance (p = .023). Sleep onset latency, wake after sleep onset and daytime fatigue showed no difference from placebo at all. (Bonn-Miller et al., 2024, Exp Clin Psychopharmacol 32(3):277-284, PMID 37796540.)
In the second trial (Lavender et al., 2026), 20 adults with physician-diagnosed insomnia disorder took 30 mg, 300 mg and placebo on separate nights under overnight polysomnography. The primary endpoint was wake after sleep onset, and CBN did not significantly change it at either dose (300 mg: p = 0.29; 30 mg: p = 0.50). At 300 mg the trial did report more stage-2 non-REM sleep, better subjective sleep quality, shorter sleep onset latency and fewer EEG arousals. All of them rank below the primary in the trial's registered outcome hierarchy. (Lavender et al., 2026, J Sleep Res 35(4):e70284, PMID 41698831, trial registration NCT05344170.)
Tolerability goes in the same breath. The polysomnography trial reported 247 mild-to-moderate adverse events across its arms. The seven-night trial (Bonn-Miller et al., 2024) reported no impact on daytime fatigue at 20 mg: worth knowing, and not a clean bill of health. Neither trial ran long enough to say anything about repeated nightly use over months; the longest CBN exposure in any published controlled trial is measured in weeks.
Read the halves together; we never print either alone. Positive secondary measures on their own read like a working sleep aid, which CBN has not shown itself to be; they are what CBN produced while missing the question each trial set itself. The opposite error matters just as much: a missed primary endpoint is a finding, not an absence. These trials asked the question properly and got an answer. Anyone who says there is “no evidence” on CBN and sleep is as wrong as anyone who says it is proven.
Verified against their PubMed records and cited in prose. Neither paper is yet a graded entry in the CBG Atlas registry, so neither carries an evidence grade here. Disclosed interest: all nine authors of the seven-night trial work for cannabinoid companies, eight at Canopy Growth Corporation and one at Wana Brands. The polysomnography trial is academic, with a single night per arm in twenty people.
Whatever you make of those trials, the most practical point about CBN is arithmetic. Every CBN dose that produced any measured signal is four to sixty times the dose typically sold. A 2021 review of the CBN sleep claim put the retail figure on record and called for trials using “dosages significantly higher than those found in currently available cannabis products marketed for sleep (typically ≤5 mg)”. Its overall conclusion, verbatim, was that “there is insufficient published evidence to support sleep-related claims”. (Corroon, 2021, Cannabis Cannabinoid Res 6(5):366-371, PMID 34468204.)
The trials since then have tested only doses well above that figure. The lowest dose that moved anything is 20 mg, four times that benchmark. The dose behind the polysomnography trial's positive measures is 300 mg, sixty times it, and in that same trial 30 mg moved essentially nothing (Lavender et al., 2026). So the published record says very little about what a ≤5 mg product does, and what it does say points the wrong way.
Read that as an absence, not a refutation. Nobody has shown that a retail dose fails, because nobody has properly tested one. The answer to a dose gap is not to take more. Taking a multiple of a label dose to reach a trial dose is self-experimentation with a compound whose repeated-use safety in people is uncharacterised, and it is not a strategy this evidence supports.
Verified against its PubMed record and cited in prose. The paper has yet to become a graded entry in the CBG Atlas registry, so it stays ungraded here. A single-author narrative review, valuable because it searched specifically for the trials the marketing implies exist, and reported what it found.
No published study has measured residual THC in products sold as CBN. We will not invent one. The question is fair: CBN is produced from THC, and a compound made by degrading THC is an obvious place for THC to be left behind. A fair question still falls short of a finding.
What does exist is adjacent evidence about labelling, in a different product category, offered here on that basis only. A survey of 500 commercially available cannabis oils in Argentina, analysed by mass spectrometry, included 17 products with a “THC-free” label claim. Of those 17, thirteen (76.5%) tested positive for Δ9-THC. The authors report wide variability in cannabinoid content, purity and labelling across the whole sample. (Fernández et al., 2023, Forensic Sci Int 349:111762, PMID 37392612, doi:10.1016/j.forsciint.2023.111762.)
That is a fact about cannabis oils in one market in 2023. It is not a fact about CBN products, and it must never be quoted as one. It supports a general and modest point: a cannabinoid label is a claim, not a test result, and in that survey a “free of X” claim was wrong for most of the products that made it. The practical response is the familiar one. Read the product's certificate of analysis and check that it names the batch in your hand. If a specific cannabinoid matters to you for testing, employment or medical reasons, treat an untested label as unverified.
Verified against its PubMed record and cited in prose. The paper has yet to become a graded entry in the CBG Atlas registry, so it stays ungraded here. It could not carry a CBN grade in any case, because it is not a CBN study. It is cited as an explicit analogy about labelling practice. Its limits (one country, one year, cannabis oils rather than isolate sleep products, and only 17 products in the THC-free subgroup) are why it is an analogy and not a measurement.
CBN is not a substitute for a prescribed hypnotic, or for any other prescribed medicine, and nothing on this page supports stopping or replacing one. CBN is not an approved medicine in any jurisdiction, for any indication. The two trials that pre-specified a primary endpoint did not meet it. Persistent insomnia is worth taking to a clinician in its own right: it is often a symptom of something treatable, and a reference page cannot assess that. This is educational information, not medical advice, and nothing here diagnoses, treats, cures or prevents any disease.
Narrative review · published 2021, before all three CBN sleep trials
Randomised placebo-controlled trial · human · primary endpoint NOT met
Randomised placebo-controlled crossover trial · human · polysomnography · primary endpoint NOT met
Preclinical · liver-enzyme assays and mice · not an interaction study in people
Not a CBN study · a label-accuracy survey of cannabis oils, cited only as an analogy
Five sources, each real, published and checkable, and all outside the CBG Atlas registry, which holds no CBN study at all; so they are cited in prose and kept out of the study feeds. The last of the five is not a CBN paper: it is a label-accuracy survey of cannabis oils, cited once as an analogy and labelled as one wherever it appears. Under each title sits its study design, the thing that limits it, and never an evidence grade; every grade on this site comes from our evidence registry. The full efficacy record, including the two large trials left out here, is set out elsewhere on this page.
Informational only, not medical advice. CBG Atlas is a scientific reference. Nothing here diagnoses, treats, cures or prevents any disease. Every claim on the page carries the grade of the evidence behind it, and the grade sets the words the claim may use. How we grade evidence.
Cardiovascular note. CBG is a potent α2-adrenoceptor agonist in vitro, and α2 agonism can lower blood pressure. Anyone taking blood-pressure or other cardiovascular medication should consult a clinician before use. This is educational information, not medical advice.
Funding and independence. Peregrine Biopharma funds the platform and holds no editorial authority.
Report a safety event →Seven compounds, each with its own monograph. The line under each one is what the verified registry actually holds for it — including where that is nothing yet.
The mother cannabinoid. CBGa decarboxylates to CBG, and both occur in the plant. The three synthases act on CBGa, the acid, branching it into THC, CBD and CBC. CBG carries more evidence than any other compound on the platform.
The acid CBG comes from, and the shared substrate the three branch synthases compete for. Heat decarboxylates it to CBG.
The propyl (varin) analogue of CBG, with a three-carbon side chain in place of five.
One of the three branches off the shared CBGA substrate, and a non-intoxicating one.
CBD's propyl analogue, and the varin with the largest published human trial record.
THC's propyl analogue, which in laboratory work behaves differently from THC at its receptors.
Families
Head-to-head